Filing Details
- Accession Number:
- 0001645627-17-000100
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-27 14:45:12
- Reporting Period:
- 2017-07-25
- Filing Date:
- 2017-07-27
- Accepted Time:
- 2017-07-27 14:45:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528172 | Endonovo Therapeutics Inc. | ENDV | Pharmaceutical Preparations (2834) | 452552528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645627 | Scott Michael Mann | 6320 Canoga Avenue Woodland Hills CA 91367 | President | No | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-07-25 | 5,000 | $0.03 | 22,009,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 3,000 | $0.04 | 22,012,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 2,000 | $0.04 | 22,014,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 2,000 | $0.04 | 22,016,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 3,500 | $0.04 | 22,019,889 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 3,500 | $0.04 | 22,023,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-25 | 2,000 | $0.04 | 22,025,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-26 | 3,000 | $0.04 | 22,028,389 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-07-26 | 3,000 | $0.04 | 22,031,389 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |